Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant

Fozza, Claudio

doi:10.1016/j.critrevonc.2018.11.001

Cited by 5 publications

(3 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing evidence indicates that the pathogenesis and progression of MDS are influenced by immune mechanisms, suggesting that treatments that modulate the responses of innate and adaptive immunity by targeting immune checkpoints, tumor antigens (vaccines), and the inflammasome may be active [ 83 , 84 ].…”

Section: Emerging Treatments For Patients With Lr-mdsmentioning

confidence: 99%

“…Immune-based therapies and inflammatory pathways in LR-MDS Increasing evidence indicates that the pathogenesis and progression of MDS are influenced by immune mechanisms, suggesting that treatments that modulate the responses of innate and adaptive immunity by targeting immune checkpoints, tumor antigens (vaccines), and the inflammasome may be active [83,84]. Allogeneic HSCT remains the only known curative approach for many myeloid malignancies, including MDS, thought in part related to a "graft-versus-leukemia" effect from immune mediator cells [85].…”

Section: Oral Hmasmentioning

confidence: 99%

See 1 more Smart Citation

Management of patients with lower-risk myelodysplastic syndromes

et al. 2022

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis with abnormal blood cell development (dysplasia) leading to cytopenias and an increased risk for progression to acute myeloid leukemia (AML). Patients with MDS can generally be classified as lower- (LR-MDS) or higher-risk (HR-MDS). As treatment goals for patients with LR-MDS and those with HR-MDS differ significantly, appropriate diagnosis, classification, and follow-up are critical for correct disease management. In this review, we focus on the diagnosis, prognosis, and treatment options, as well as the prediction of the disease course and monitoring of treatment response in patients with LR-MDS. We discuss how next-generation sequencing, increasing knowledge on mechanisms of MDS pathogenesis, and novel therapies may change the current treatment landscape in LR-MDS and why structured assessments of responses, toxicities, and patient-reported outcomes should be incorporated into routine clinical practice.

show abstract

Section: Emerging Treatments For Patients With Lr-mdsmentioning

confidence: 99%

Section: Oral Hmasmentioning

confidence: 99%

Management of patients with lower-risk myelodysplastic syndromes

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In contrast, blastic progression and risk of AML transformation are the major concerns of High-Risk MDS (HR-MDS) patients, and treatments target the malignant clone [6]. In both situations, however, available therapeutic options are limited, and a better comprehension of MDS pathophysiology is needed to identify new targets [7].…”

Section: Introductionmentioning

confidence: 99%

From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review

2021

View full text Add to dashboard Cite

The pathophysiology of myelodysplastic syndromes (MDSs) is complex and often includes immune dysregulation of both the innate and adaptive immune systems. Whereas clonal selection mainly involves smoldering inflammation, a cellular immunity dysfunction leads to increased apoptosis and blast proliferation. Addressing immune dysregulations in MDS is a recent concept that has allowed the identification of new therapeutic targets. Several approaches targeting the different actors of the immune system have therefore been developed. However, the results are very heterogeneous, indicating the need to improve our understanding of the disease and interactions between chronic inflammation, adaptive dysfunction, and somatic mutations. This review highlights current knowledge of the role of immune dysregulation in MDS pathophysiology and the field of new drugs.

show abstract

Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: A multiple-treatments network meta-analysis

Zhou

et al. 2020

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant

Cited by 5 publications

References 111 publications

Management of patients with lower-risk myelodysplastic syndromes

Management of patients with lower-risk myelodysplastic syndromes

From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review

Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: A multiple-treatments network meta-analysis

Contact Info

Product

Resources

About